Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: Long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients - Neggers, S J; de Herder, W W; Janssen, J A (Eur J Endocrinol, 2009)
et al.